Toll-like receptors and NOD-like receptors in rheumatic diseases.
AffiliationOPSONA Therapeutics Ltd, Institute of Molecular Medicine, Trinity Centre for, Health Sciences, St James' Hospital, Dublin 8, Ireland. firstname.lastname@example.org
Nod Signaling Adaptor Proteins/immunology/*metabolism
MetadataShow full item record
CitationArthritis Res Ther. 2009;11(5):243. Epub 2009 Oct 14.
JournalArthritis research & therapy
AbstractThe past 10 years have seen the description of families of receptors that drive proinflammatory cytokine production in infection and tissue injury. Two major classes have been examined in the context of inflammatory joint disease--the Toll-like receptors (TLRs) and NOD-like receptors (NLRs). TLRs such as TLR2 and TLR4 are being implicated in the pathology of rheumatoid arthritis, ankylosing spondylitis, lyme arthritis and osteoarthritis. Nalp3 has been identified as a key NLR for IL-1beta production and has been shown to have a particular role in gout. These findings present new therapeutic opportunities, possibly allowing for the replacement of biologics with small molecule inhibitors.